Tolterodine ER

DRUG9 trials

Conditions

CognitionMemoryOveractive BladderOveractive Bladder (OAB)Overactive Urinary BladderUreteral ObstructionUrinary Bladder, OveractiveUrinary Incontinence

Phase 1

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

TerminatedNCT01500382

Merck Sharp & Dohme LLCOveractive Bladder, Overactive Urinary Bladder

Start: 2012-02-27End: 2013-01-02Updated: 2018-12-24

Phase 2

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

CompletedNCT01314872

Merck Sharp & Dohme LLCUrinary Bladder, Overactive

Start: 2011-03-31End: 2013-10-10Updated: 2019-02-04

Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

CompletedNCT00611026

PfizerOveractive Bladder

Start: 2008-02-29End: 2009-10-31Updated: 2011-02-02

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

CompletedNCT01043666

Astellas Pharma IncUrinary Bladder, Overactive

Start: 2009-12-21End: 2011-09-16Updated: 2024-10-31

Phase 4

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

CompletedNCT00137397

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Urinary Incontinence

Start: 2004-11-30End: 2006-08-31Target: 80Updated: 2021-01-27

Effects Of Detrol LA On Memory And Cognition In Elderly Population

CompletedNCT00411437

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Cognition, Memory

Start: 2006-12-31End: 2007-06-30Target: 220Updated: 2021-01-27

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

TerminatedNCT01302938

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Overactive Bladder

Start: 2011-03-31End: 2012-08-31Updated: 2021-01-28

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

CompletedNCT01741454

University of Wisconsin, MadisonUreteral Obstruction

Start: 2012-11-30End: 2018-03-30Updated: 2019-07-10

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

CompletedNCT02138747

Astellas Pharma Global Development, Inc.Overactive Bladder (OAB)

Start: 2014-07-24End: 2015-11-11Updated: 2020-02-26

Related Papers

A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder.

2022-07-261 citations

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

2018-10-2543 citations

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).

2018-04-1913 citations

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).

2017-06-1524 citations